Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Cyber Monday Deal: Up to 55% off CLAIM SALE
Close

Teva Pharma Industries Ltd ADR (TEVA)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Teva ADR's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
9.89 +0.34    +3.56%
27/11 - Closed. Currency in USD ( Disclaimer )
Pre Market
9.90
0.01
0.10%
6:56:21 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 16,251,449
  • Bid/Ask: 9.83 / 9.90
  • Day's Range: 9.70 - 10.07
Teva ADR 9.89 +0.34 +3.56%

Teva Pharma Industries Ltd ADR Company Profile

 
Get an in-depth profile of Teva Pharma Industries Ltd ADR, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

34565

Equity Type

ADR

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company’s products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia, as well as a collaboration with Sanofi to co-develop and co-commercialize TEV-48574 asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn’s disease. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Contact Information

Address 124 Dvora Hanevi’a Street
Tel Aviv, 6944020
Israel
Phone 972 3 914 8213
Fax -
Web www.tevapharm.com

Top Executives

Name Age Since Title
Sol J. Barer 75 2015 Independent Chairman of the Board
Amir Elstein 67 2005 Independent Director
Roberto Agostino Mignone 51 2017 Independent Director
Rosemary A. Crane 63 2015 Independent Director
Gerald M. Lieberman 76 2015 Independent Director
Janet S. Vergis 59 2020 Independent Director
Tal Zaks 57 2021 Independent Director
Perry D. Nisen 67 2017 Independent Director
Ronit Satchi-Fainaro 51 2018 Independent Director
Varda Shalev 63 2023 Independent Director
Richard D. Francis 55 2023 President, CEO & Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

TEVA Comments

Write your thoughts about Teva Pharma Industries Ltd ADR
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ramba Łej
Kubizm Sep 14, 2023 10:26AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
11,40 will hold as celling or convert to floor :)?
Reply
0 0
Report
Ramba Łej
Kubizm Aug 02, 2023 8:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
looking good on pre-market. Wonder how USA downgrade might spoil the fun here
Reply
1 0
Report
BumHunters Archer
JohnJenga Aug 02, 2023 8:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
25 next year seems quite doable
Reply
0 0
Report
Michael Christensen
Michael Christensen Aug 02, 2023 6:00AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Somebody know the consensus for Q2 today ?
Reply
1 0
Report
Harel Cohen
Harel Cohen Aug 01, 2023 10:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
first real report of new CEO... it will be interesting
Reply
2 0
Report
Thao Bui
Thao Bui Jun 09, 2023 11:03PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
OKE
Reply
0 0
Report
Ramba Łej
Kubizm May 19, 2023 1:12PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
so impressing strategy haha xD
Reply
0 0
Report
Ramba Łej
Kubizm May 18, 2023 5:28PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Reply
0 0
Report
Ramba Łej
Kubizm May 11, 2023 8:11AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
**achtung spoiler** 18th of may and the day after will be another slump. I bet new groth strategy will fail to encourage any whale
Reply
1 1
Report
Matan Miz
Matan Miz May 11, 2023 8:11AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Why ? What is the info ? What will happen .
Reply
0 0
Report
Ramba Łej
Kubizm May 11, 2023 8:11AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
as you can see today a day b4 announced strategy presentation big volume and slide, insiders know that teva will fail again to encourage investors
Reply
0 0
Report
Ramba Łej
Kubizm May 10, 2023 7:49AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
fail after fail after fail and again and again
Reply
0 0
Report
Matan Miz
Matan Miz May 10, 2023 7:49AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Patience is the name of the game .
Reply
0 0
Report
Ramba Łej
Kubizm May 10, 2023 7:49AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Matan Miz for sure, just stating a fact
Reply
0 0
Report
Tom Christensen
Tom Christensen May 10, 2023 7:49AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
im out had it in 4 years an lost alot
Reply
0 0
Report
asas avn
asas avn Apr 14, 2023 10:23AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what happened?
Reply
0 0
Report
Ramba Łej
Kubizm Apr 14, 2023 10:23AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
visit news section
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email